Sylvan Learning recently unveiled a new license agreement which aims to attract new franchisees and retain existing ones.
It’s exciting to be part of something important. Something big. So I speak on behalf of the whole Sylvan team when I say we are thrilled to be launching Sylvan EDGE. Sylvan’s new EDGE programs provide kids with hands-on, experiential classes like robotics, computer coding, game design, and engineering. The EDGE programs are designed to challenge students and inspire them to master critical skills for the future. Best of all, they’re fun!
Sylvan's CEO, Jeff Cohen, was selected as one of four visionary leaders, who represent breakthrough education models, to talk to Forbes.com about technology, economics and the future of American education. Check out the full article below:
What a week! From the hot California sun, to the insightful pre-conference sessions to the exciting new products and marketing solutions, and of course the celebration party - I think we can call the 2014 Sylvan Annual Conference a great success!
In an earlier post, we announced Sylvan's mission to raise at least $250,000 between our Centers nationwide and Corporate to benefit the Leukemia & Lymphoma Society (LLS). Our franchisees are off to a great start by donating scholarships and creating teams to fundraise and participate in their local Light the Night Walks (LTN).
Earlier this month, the board members of Sylvan's Franchise Owners Association (FOA) came to corporate headquarters for our joint quarterly leadership meeting. During the most recent meeting, we focused on the collaboration of key business initiatives. The FOA Board also received updates from Sylvan leadership about the roadmap for 2015 and beyond. The FOA Board and the Sylvan corporate team meet in person each quarter to ensure ongoing collaboration and have countless other calls to ensure follow through on initiatives.
The race is on for Sylvan Learning to raise more than $250,000 to benefit the Leukemia & Lymphoma Society (LLS)'s mission to find cures for blood cancers and ensure access to treatments for the patients who need them.